FDA Orders a Vision-Loss Warning on Every GLP-1 Drug, From Ozempic to Zepbound
The agency says GLP-1 medications may raise the risk of NAION, a rare "stroke" of the optic nerve that can permanently damage sight in one eye. Here's what changed, what the data shows, and what to do if you take one of these drugs.
The Bipartisan Push to Split PBMs From Pharmacies — and Why CVS Has the Most to Lose
Republican governors have signed the first state bans, a Democrat–Republican Senate team wants to take the idea national, and CVS Health is fighting back in court.
Red Ribbon Week: How to Help Kids Stay Drug-Free
This year's theme asks every child to be a hero. Here is how parents and caregivers can help them do it, this week and all year.
Eli Lilly Pledges to Bring GLP-1s to Lower-Income Countries
The new Lilly Change the Course Commitment aims to treat as many people with diabetes and obesity in low- and middle-income countries as in wealthy ones by 2040.
Two New FDA-Approved Treatments Give People With FOP More Options
In five weeks, the FDA approved Regeneron's Pasatru and Mirum's Atebrioz for fibrodysplasia ossificans progressiva, a rare disease that slowly turns muscle and tendons into bone.
Trump Orders a Smaller-Dose Childhood Vaccine Schedule — Here's What Actually Changed
A White House executive order is reshaping how many diseases U.S. children are routinely vaccinated against, and how their shots are delivered. Pediatric and vaccine experts say the reasoning behind it doesn't hold up — and warn the changes could mean more visits, not safer ones.